Update on the rational use of (90)Y-ibritumomab tiuxetan in the treatment of follicular lymphoma
Martina Lehnert, Heinz Ludwig, Niklas Zojer 1st Department of Medicine, Center for Oncology and Hematology, Wilhelminenspital, Vienna, AustriaAbstract: The development of radiolabeled antibodies against CD20 has facilitated targeted treatment of follicular lymphoma (FL). By using 90Y-ibritumomab tiu...
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Dove Medical Press
2009-07-01
|
| Series: | OncoTargets and Therapy |
| Online Access: | http://www.dovepress.com/update-on-the-rational-use-of-90y-ibritumomab-tiuxetan-in-the-treatmen-a3399 |